Join to view full profile
986840 Nebraska Medical CtrOmaha, NE 68198
Phone+1 402-559-8500
Fax+1 402-552-2512
Dr. Ganti is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Apar Kishor Ganti is an oncologist based in Omaha, NE, specializing in lung cancer, thyroid cancer, and head and neck oncology. He completed his fellowship in Hematology and Medical Oncology at the University of Nebraska Medical Center and his residency in Internal Medicine at the University of North Dakota. He graduated in 1996 from B.J. Medical College at the University of Pune. Dr. Ganti has contributed to numerous publications, such as research on chemoresistance, immune checkpoint inhibitors, small cell lung cancer, and pancreatic ductal adenocarcinoma, with his works being widely cited. He has been involved in several clinical trials, including those focusing on lung cancer. He has received multiple CMS Meaningful Use Stage Certifications for his work with Epic Systems Corporation.
Education & Training
University of Nebraska Medical Center College of MedicineFellowship, Hematology and Medical Oncology, 2003 - 2005
University of North DakotaResidency, Internal Medicine, 2000 - 2003
B.J. Medical College - University of PuneClass of 1996
Certifications & Licensure
NE State Medical License 2005 - 2026
ND State Medical License 2001 - 2003
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Inpatient - Core EMR, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2014, 2016-2017
Clinical Trials
- Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
- Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy Start of enrollment: 2014 Apr 14
- Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab Start of enrollment: 2023 Dec 13
Roles: Contact
Publications & Presentations
PubMed
- 14 citationsElevated PAF1-RAD52 axis confers chemoresistance to human cancers.Sanchita Rauth, Koelina Ganguly, Pranita Atri, Seema Parte, Rama Krishna Nimmakayala
Cell Reports. 2023-02-28 - 35 citationsHypophysitis and Secondary Adrenal Insufficiency From Immune Checkpoint Inhibitors: Diagnostic Challenges and Link With Survival.Jake Johnson, Whitney Goldner, Duaa Abdallah, Fang Qiu, Apar Kishor Ganti
Journal of the National Comprehensive Cancer Network. 2023-02-24 - 73 citationsMicroRNA-1 attenuates the growth and metastasis of small cell lung cancer through CXCR4/FOXM1/RRM2 axis.Parvez Khan, Jawed Akhtar Siddiqui, Prakash G Kshirsagar, Ramakanth Chirravuri Venkata, Shailendra Kumar Maurya
Molecular Cancer. 2023-01-04
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
